Analysis of Attitudes and Practices towards the Influenza Vaccine in High-Risk Adults in Poland

This study aimed to understand Poles' attitudes and beliefs towards influenza vaccinations in the flu season of 2022-2023, especially among individuals at risk of flu complications. The cross-sectional survey-based study was carried out on a sample of 810 respondents. The questionnaire was disseminated electronically using social media and e-mail. The majority of respondents (71%) could identify "high-risk groups" recommended for influenza vaccination, and 52.01% of respondents reported receiving influenza vaccination at some point in the past, with 32.12% receiving it in the 2022-2023 flu season and 41.09% in the 2021-2022 season. The majority of respondents declaring acceptance of the vaccine for the 2022-2023 season were in the high-risk group. Only 17.28% of respondents declared receiving both influenza and SARS-CoV-2 vaccines in the 2022-2023 season, with the vast majority being respondents from the "high-risk group" (p < 0.0001). Only 26.12% of respondents declared their intention to continue influenza vaccination in the future. Of those expressing the intention to get vaccinated against the influenza virus in future seasons, 46.79% were from the "high-risk group" (p = 0.0087). Results suggest the need for further interaction and education with healthcare providers and targeted informational efforts for at-risk groups regarding the benefits of flu vaccination.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:12

Enthalten in:

Vaccines - 12(2024), 3 vom: 21. März

Sprache:

Englisch

Beteiligte Personen:

Kopciuch, Dorota [VerfasserIn]
Hoffmann, Karolina [VerfasserIn]
Kus, Krzysztof [VerfasserIn]
Koligat-Seitz, Agnieszka [VerfasserIn]
Ratajczak, Piotr [VerfasserIn]
Nowakowska, Elżbieta [VerfasserIn]
Paczkowska, Anna [VerfasserIn]

Links:

Volltext

Themen:

Attitudes
High-risk groups
Influenza
Journal Article
Practice
Vaccines

Anmerkungen:

Date Revised 30.03.2024

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/vaccines12030341

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM370335236